The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,810.00
Bid: 1,811.00
Ask: 1,811.50
Change: 0.00 (0.00%)
Spread: 0.50 (0.028%)
Open: 1,805.00
High: 1,812.50
Low: 1,797.00
Prev. Close: 1,810.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Bank rules force staff to turn off NHS COVID-19 tracing app at work

Thu, 08th Oct 2020 13:32

* Thousands of staff seen at risk of undetected infection -
union

* Some banks ask staff to store phones away to prevent data
leaks

* Govt advises NHS app should be paused if phone not on
person
(Adds Department of Health comment)

By Iain Withers and Sinead Cruise

LONDON, Oct 8 (Reuters) - Branch staff at some of Britain's
biggest banks say rules that require them to store phones in
lockers while at work are putting them at undue risk of COVID-19
from colleagues and customers, as they cannot use the country's
tracing app.

Lloyds Banking Group, along with rival TSB, are
among those advising employees to deactivate the NHS Track &
Trace app during office hours, when they are not allowed to keep
phones on their person.

Some banks ask staff and cashiers to store phones away to
prevent leaks of sensitive customer data, although this is not
formally required by regulator the Financial Conduct Authority.

Under current government guidelines, users of the NHS app
are advised to disable bluetooth or pause the app when away from
their phones to avoid false notifications.

Other companies have told staff to pause the app at work,
including pharmaceuticals firm GSK, which said its other
safety measures were sufficient, the Guardian newspaper
reported.

The BTU union, which represents staff working for Lloyds but
is not recognised by the bank, said it had been contacted by
dozens of staff unable to use the app, which has been downloaded
by more than 14 million people.

One unnamed Lloyds employee who contacted the BTU said: "I
live and work in a high-risk area so I am very concerned at
being told that while I'm at work I have to suspend the NHS test
and trace app... This defeats the object of track and trace."

Another said they were at risk as they had to conduct
face-to-face meetings and due to the "blatant transgression of
the social distancing rules by many customers".

"Customers and staff have a right to know if they have come
into contact with someone who's been infected," said Mark Brown,
general secretary of the BTU.

Although several European countries have launched
Bluetooth-based apps to alert those at risk of catching
COVID-19, there is little evidence to date that the technology
has significantly curbed infections.

Both Lloyds and TSB have advised staff to pause the app's
tracing function while at work, according to internal guidance
issued by each lender seen by Reuters.

"Colleagues who have downloaded the app to their own smart
phone should not use the app while you are at work," Lloyds told
staff, adding it was to stop people receiving false alerts.

A NatWest spokesman said the bank encouraged staff to use
the app but said they should pause it when they are not with
their phone. The bank discourages - though doesn't ban - the use
of personal phones in branches and contact centres.

A spokesman for Barclays said the bank had not advised staff
to turn off the app.

A Department of Health and Social Care spokeswoman said: "We
want as many people to download and use the app as possible. It
is important to use the NHS Covid-19 app at all times, including
while at work, unless in specific scenarios which are clearly
set out in our guidance."

TSB was not immediately available for comment. Lloyds
declined to comment.

A second employee union, Accord, said rules prohibiting use
of personal phones in the workplace were in place to protect
employees from security risks.

"If customers care about the health and well-being of the
bank staff they rely on, they could help by wearing face
coverings when visiting bank branches," Accord's General
Secretary Ged Nichols said.
(Reporting by Iain Withers and Sinead Cruise; Additional
reporting by Douglas Busvine in Berlin; Editing by Rachel
Armstrong, Jan Harvey and Toby Chopra)

More News
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more
16 Oct 2023 07:16

GSK nears green light for Jemperli usage in Europe

(Sharecast News) - Pharma giant GSK has announced that European experts recommended the approval of its Jerperli drug for the treatment of a specific type of endometrial cancer - paving the way for marketing authorisation by the continent's regulatory body.

Read more
11 Oct 2023 11:51

GSK settles California Zantac lawsuit

(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.